ProPhase Labs Inc (NASDAQ:PRPH) was the target of a large decline in short interest during the month of November. As of November 29th, there was short interest totalling 11,000 shares, a decline of 12.7% from the November 14th total of 12,600 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average trading volume of 2,500 shares, the days-to-cover ratio is presently 4.4 days.
Shares of PRPH stock traded down $0.08 during trading on Friday, reaching $2.03. 2,891 shares of the company’s stock were exchanged, compared to its average volume of 6,108. ProPhase Labs has a twelve month low of $1.63 and a twelve month high of $4.00. The firm’s fifty day moving average price is $1.94 and its 200-day moving average price is $2.13.
ProPhase Labs (NASDAQ:PRPH) last posted its earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $2.77 million for the quarter. ProPhase Labs had a negative return on equity of 20.48% and a negative net margin of 29.05%.
A hedge fund recently bought a new stake in ProPhase Labs stock. Susquehanna International Group LLP bought a new position in shares of ProPhase Labs Inc (NASDAQ:PRPH) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 13,717 shares of the company’s stock, valued at approximately $29,000. Susquehanna International Group LLP owned about 0.12% of ProPhase Labs at the end of the most recent quarter. Institutional investors own 4.25% of the company’s stock.
About ProPhase Labs
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Featured Story: Initial Coin Offerings entail a high degree of risk
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.